SmartCardia's 7-Lead ECG Patch Receives FDA Clearance for Outpatient Cardiac Telemetry
核心洞察
SmartCardia (搜索)'s 7-lead ECG patch and cloud platform have received FDA clearance for Mobile Outpatient Cardiac Telemetry (OCT/MCT).
The patch allows for continuous ECG monitoring for up to 14 days and seamless transition between Holter and mobile telemetry modes.
The platform features real-time ECG data streaming to the cloud, providing immediate notifications and full-disclosure ECG analysis for clinicians.
SmartCardia (搜索) has announced FDA clearance for its 7-lead ECG patch and cloud platform for Mobile Outpatient Cardiac Telemetry (OCT/MCT), marking a significant advancement in remote cardiac monitoring. The clearance enables continuous monitoring for up to 14 days, offering clinicians real-time data and immediate notifications for critical arrhythmias (搜索).
The SmartCardia (搜索) 7L patch is designed for ease of use, being cable-free and waterproof. It builds upon the company's previous FDA clearances for Extended Holter, Event, and Holter monitoring, providing a comprehensive solution for cardiology practices. The patch can be remotely transitioned between monitoring modes, enhancing patient convenience and clinical flexibility.
Enhanced Accuracy and Real-Time Monitoring
The 7-lead ECG data is streamed live to SmartCardia (搜索)'s proprietary cloud platform, where it undergoes continuous analysis. This full-disclosure analysis allows for highly accurate arrhythmia detection, and the platform's intuitive interface facilitates easy review and analysis of ECG data by clinicians at any time. Visual and audio alarms are also delivered for immediate notification of critical events.
According to Dr. Jag Singh from Harvard Medical School and Massachusetts General Hospital, and Principal Advisor of SmartCardia (搜索), "SmartCardia's platform effectively addresses the primary needs of today's electrophysiologists and cardiologists. Its 7-lead ECG delivers unparalleled clinical accuracy, the live monitoring allows for immediate notifications, and the reusable sensor with a low cost disposable patch promotes high operational efficiency."
Addressing Unmet Needs in Cardiac Monitoring
Many existing products lack explicit FDA clearance for outpatient cardiac telemetry. SmartCardia (搜索)'s patch and cloud platform are specifically designed to meet stringent outpatient telemetry standards, ensuring accurate and timely detection of arrhythmia events. Adam Kirchgessner, SmartCardia's US VP of Sales, emphasized the company's commitment to providing an end-to-end solution from patch to cloud.
Expanding Capabilities and Global Reach
SmartCardia (搜索) has recently acquired a US Independent Diagnostic Testing Facility (IDTF), further integrating its services and ensuring control over the entire ecosystem. The company also has "in-network" coverage with major insurers across the US for various monitoring modalities. SmartCardia's solution holds CE Class IIa approval in Europe for ECG, analysis, cloud, and vital signs, and the company is actively expanding its presence in multiple countries.
SmartCardia (搜索) was also honored with the 2022 Global New Product Innovation Award in cardiac monitoring from Frost & Sullivan, highlighting its commitment to innovation and excellence in the field.